The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.
- First select the CSR Section, then a Table/Figure from that section.
- Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.
To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.
Download and Print: Download Printer-friendly PDF Download data
Table 22.8
Cancer of the Pancreas (Invasive)
5-Year Relative and Period Survival by Race, Sex, Diagnosis Year, Age and Stage at Diagnosis
5-Year Relative Survival (Percent) by Year of Diagnosis
| Year of Diagnosis |
All Races | Whites | Blacks | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both Sexes | Males | Females | Both Sexes | Males | Females | Both Sexes | Males | Females | |
| 1960-1963a | - | - | - | 1 | 1 | 2 | 1 | 0 | 3 |
| 1970-1973a | - | - | - | 2 | 2 | 2 | 2 | 0 | 3 |
| 1975-1977b | 2.5 | 2.6 | 2.2 | 2.5 | 2.7 | 2.3 | 2.3 | 2.5 | 1.9 |
| 1978-1980b | 2.9 | 2.7 | 3.0 | 2.5 | 2.6 | 2.5 | 5.8 | 4.5 | 7.0 |
| 1981-1983b | 2.7 | 2.4 | 3.1 | 2.5 | 2.1 | 3.0 | 3.6 | 3.7 | 3.2 |
| 1984-1986b | 2.9 | 2.3 | 3.5 | 2.6 | 2.1 | 3.1 | 4.7 | 3.9 | 5.3 |
| 1987-1989b | 3.5 | 3.3 | 3.7 | 3.2 | 3.0 | 3.3 | 5.5 | 5.1 | 5.8 |
| 1990-1992b | 4.3 | 4.1 | 4.5 | 4.4 | 4.2 | 4.5 | 3.6 | 3.2 | 4.0 |
| 1993-1995b | 4.0 | 3.7 | 4.3 | 3.9 | 3.6 | 4.2 | 3.7 | 3.6 | 3.7 |
| 1996-1998b | 4.3 | 4.6 | 4.1 | 4.1 | 4.6 | 3.6 | 3.4 | 3.1 | 3.5 |
| 1999-2001b | 5.1 | 5.2 | 5.0 | 5.0 | 5.5 | 4.5 | 5.6 | 3.7 | 7.4 |
| 2002-2004b | 5.6 | 5.3 | 5.9 | 5.7 | 5.6 | 5.8 | 4.5 | 3.0 | 5.7 |
| 2005-2009b | 7.7 | 7.8 | 7.6 | 7.8 | 7.8 | 7.7 | 6.4 | 6.8 | 6.1 |
| 2010-2016b | 10.5f | 10.7f | 10.2f | 10.4f | 10.7f | 10.2f | 10.3f | 10.5f | 10.1f |
5-Year Period Survival (Percent)cd
| Year | All Races | Whites | Blacks | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both Sexes | Males | Females | Both Sexes | Males | Females | Both Sexes | Males | Females | |
| 2016 | 11.0 | 11.0 | 11.0 | 10.8 | 10.9 | 10.7 | 10.6 | 9.8 | 11.2 |
Stage Distribution (%) 2010-2016ce, Case Counts and Percentages
| Stage at Diagnosis |
All Races | Whites | Blacks | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both Sexes | Males | Females | Both Sexes | Males | Females | Both Sexes | Males | Females | |
| Number of cases | 65,128 | 33,078 | 32,050 | 51,197 | 26,465 | 24,732 | 8,087 | 3,741 | 4,346 |
| Percent | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Localized | 11 | 10 | 12 | 11 | 10 | 12 | 11 | 9 | 12 |
| Regional | 30 | 29 | 30 | 30 | 30 | 30 | 28 | 26 | 29 |
| Distant | 52 | 55 | 50 | 52 | 54 | 50 | 56 | 59 | 53 |
| Unstaged/Unknown | 7 | 6 | 8 | 7 | 6 | 8 | 6 | 5 | 7 |
5-Year Relative Survival (Percent) 2010-2016c by Age at Diagnosis
| Age at Diagnosis |
All Races | Whites | Blacks | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both Sexes | Males | Females | Both Sexes | Males | Females | Both Sexes | Males | Females | |
| Ages <45 | 40.6 | 32.6 | 48.9 | 41.3 | 34.2 | 49.1 | 37.7 | 23.3 | 49.0 |
| Ages 45-54 | 17.1 | 15.2 | 19.6 | 16.7 | 14.6 | 19.8 | 16.2 | 15.5 | 17.1 |
| Ages 55-64 | 11.3 | 10.6 | 12.3 | 11.3 | 10.8 | 12.1 | 9.9 | 8.9 | 11.2 |
| Ages 65-74 | 9.1 | 9.2 | 9.0 | 9.1 | 9.2 | 9.0 | 8.0 | 7.4 | 8.5 |
| Ages 75+ | 4.7 | 5.2 | 4.4 | 4.8 | 5.3 | 4.4 | 4.5 | 2.7 | 5.1 |
| Ages <65 | 15.2 | 13.4 | 17.6 | 15.0 | 13.4 | 17.3 | 13.9 | 11.7 | 16.4 |
| Ages 65+ | 6.8 | 7.4 | 6.3 | 6.8 | 7.4 | 6.3 | 6.4 | 5.8 | 6.7 |
5-Year Relative Survival (Percent) 2010-2016c by Stage at Diagnosise
| Stage at Diagnosis |
All Races | Whites | Blacks | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Both Sexes | Males | Females | Both Sexes | Males | Females | Both Sexes | Males | Females | |
| All Stages | 10.0 | 10.0 | 10.0 | 9.8 | 9.9 | 9.8 | 10.1 | 9.2 | 10.8 |
| Localized | 39.4 | 40.9 | 38.1 | 39.2 | 41.2 | 37.3 | 36.0 | 33.5 | 37.5 |
| Regional | 13.3 | 14.0 | 12.6 | 13.2 | 13.7 | 12.5 | 14.5 | 15.3 | 13.8 |
| Distant | 2.9 | 2.9 | 3.0 | 2.9 | 2.9 | 3.0 | 2.9 | 2.8 | 2.9 |
| Unstaged/Unknown | 6.1 | 6.6 | 5.6 | 5.4 | 6.2 | 4.5 | 11.1 | 9.2 | 12.5 |
Footnotes:
a Based on End Results data from a series of hospital registries and one population-based registry.
b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Based on follow-up of patients into 2017. Expected survival rates are derived from the U.S. Annual Life Tables.
c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program. Based on follow-up of patients into 2017.
d Period survival provides a 2016 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).
e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.
f The difference between 1975-1977 and 2010-2016 is statistically significant (p<.05).
g The standard error is between 5 and 10 percentage points.
h The standard error is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 25 cases during the time period.
Page Navigation: << Previous Next >>
The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.